First Tracks reports Q2 2026 results, ANB033 gets FDA Fast Track in celiac disease
The company finished enrollment in a gluten-challenge cohort of its Phase 1b celiac trial and expanded a second cohort, while reiterating a cash runway into Q2 2028.
SEC filing